StockNews.AI
IMCC
StockNews.AI
152 days

IM Cannabis to Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 31 2025 at 9:00am ET

1. IMC will report Q4 and full year 2024 results on March 31, 2025. 2. A Zoom conference will discuss the results at 9:00 AM ET. 3. The company operates in Israel and Germany, focusing on medical cannabis. 4. IMC utilizes a data-driven approach for product sourcing and distribution. 5. They aim for sustainable growth in high-value cannabis markets.

Earnings
+12.72%Current Return
VS
-0.91%S&P 500
$1.670103/20 07:06 AM EDTEvent Start
$1.882503/21 01:28 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings reports generally heighten investor interest and may enhance IMC's stock value.

How important is it?

Earnings announcements typically lead to significant stock movement; IMC's operations are promising.

Why Short Term?

The immediate focus will be on Q4 results, affecting stock price quickly.

Related Companies

CSE: IMCCNASDAQ: IMCC
, /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company," "IMCannabis," or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the fourth quarter and full year 2024 ended December 31, 2024, on Monday, March 31, 2025 before the market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com within 24 hours after the call. Link to register for the zoom call: https://us02web.zoom.us/webinar/register/WN_RJjroBAjSOSRZLqGuM8CCw About IM Cannabis Corp. IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player. The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg Company Contact: Anna Taranko, Director Investor & Public Relations IM Cannabis Corp. +49 157 80554338 [email protected] Oren Shuster, CEO IM Cannabis Corp. +972-77-3603504 [email protected] SOURCE IM Cannabis Corp. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News